RARE DISEASERESEARCH ATLAS
Open navigation menu

ORPHA:36258

Buerger disease

medium confidenceDisorder

Also known as: Thromboangiitis obliterans

Publications

5,600

87.9th percentile

Trials

11

Interventional, condition-specific

Researchers

952

Distinct authors in sample

Gene link

—

Readiness

4/6

Stages with a signal

Clinical definition (Orphanet)

A rare systemic disease characterized by inflammatory, non-necrotizing, non-atherosclerotic, occlusive vascular disease with thrombosis and recanalization affecting small and medium sized arteries and veins of upper and lower extremities.

How rare: 1-5 / 10 000 — about one to five people per ten thousand (still uncommon, but less ultra-rare).

Orphanet entry

Cross-references

Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.

Additional Mondo synonyms (4)

Buerger's Disease · Buerger's disease · thromboangiitis obliterans · thromboangiitis obliterans [Buerger's disease]

Research stages

Trial readiness signals

Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”

4/6 stages with a signal

An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.

  1. Gene identifiedNot found

    No GenCC disease–gene assertion in this build

  2. LiteraturePresent

    5,600 matched papers (1,149 in last 10 years) Source

  3. Phenotype characterisedPresent

    21 HPO annotations (e.g. Pain; Limb pain; Raynaud phenomenon) Source

  4. Animal modelNot found

    No Alliance genotype “model of” associations via Monarch for these Mondo IDs

  5. Orphan designationPartial

    3 EMA designations (none yet with FDA orphan-indication approval) — e.g. adult human bone-marrow-derived, ex-vivo-expanded, pooled allogeneic mesenchymal stromal cells Source

  6. Interventional trialPresent

    11 matched on ClinicalTrials.gov (3 recruiting in sample)

Biology

Genes and phenotypes

Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.

Do we know what causes it?

Not yet — the cause hasn't been pinned down in GenCC.

No strong gene–disease assertion joined for this Orphanet entity.

Phenotypes (Monarch / HPO)

21

Associated phenotypes · MONDO:0008889

  • Pain
  • Limb pain
  • Raynaud phenomenon
  • Hyperhidrosis
  • Sensory neuropathy

Showing 5 of 21 — open Monarch for the full list.

Animal models (Monarch / Alliance)

None returned for this Mondo ID. Empty here is not proof that no model organism work exists under another name or gene.

Monarch fetch 2026-07-29

Therapies

Designations, candidates, and chemicals

FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.

Orphan designation (FDA · EMA)

3

Designations · no FDA orphan-indication approval yet

  • EMA adult human bone-marrow-derived, ex-vivo-expanded, pooled allogeneic mesenchymal stromal cellsTreatment of thromboangiitis obliterans (Buerger's disease) · 21/05/2015 · PositiveEMA designation
  • EMA autologous bone-marrow-derived mononuclear-cell fractionTreatment of thromboangiitis obliterans (Buerger's disease) · 20/09/2010 · PositiveEMA designation
  • EMA autologous adipose tissue-derived mesenchymal stem cellsTreatment of thromboangiitis obliterans (Buerger's disease) · 20/03/2017 · WithdrawnEMA designation

Sources: FDA OOPD · EMA orphan designations

Open Targets candidates

5

Drugs / clinical candidates · MONDO_0008889

CTD chemicals (MyDisease.info)

5 associated chemicals. Therapeutic evidence is listed first when present — not a treatment recommendation.

  • Alprostadil · therapeutic
  • Cocaine · marker/mechanism
  • Ethinyl Estradiol · marker/mechanism
  • Nicotine · marker/mechanism
  • Tobacco Smoke Pollution · marker/mechanism

MyDisease.info · MONDO:0008889

Literature

Is anyone studying this?

5,600

5,600 papers — among the better-studied rare conditions, though still a fraction of common-disease literature (breast cancer: over 700,000). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.

5,600 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).

1,149 in the last 10 years · medium confidence · 87.9th percentile (publications denominator)

Phrase hits: 5,600 · MeSH hits: 0

Open Europe PMC search

Who's working on it?

952

Distinct author names in 200 sampled papers — named people below.

Who's working on it?

People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.

  1. 01
    Li J6 papers · 2026

    Department of General Surgery, Shanghai Pudong Hospital, Fudan University Pudong Medical Center, Shanghai Key Laboratory of Vascular Lesions Regulation and Remodeling, Shanghai, 201399, China.

    Papers in Europe PMC
  2. 02
    Zhang Y6 papers · 2026

    Department of Orthopaedics, Xiangya Hospital, Central South University, Changsha, Hunan, People's Republic of China.

    Papers in Europe PMC
  3. 03
    Chen J5 papers · 2026

    Guangzhou Institute of Cardiovascular Disease, Guangdong Key Laboratory of Vascular Diseases, State Key Laboratory of Respiratory Disease, The Second Affiliated Hospital, Guangzhou Medical University, Guangzhou, China. Electronic address: 2021390029@gzhmu.edu.cn.

    Papers in Europe PMC
  4. 04
    Ghaderi A5 papers · 2026

    Department of Addiction Studies, School of Medical, Kashan University of Medical Sciences, Kashan, Iran.

    Papers in Europe PMC
  5. 05
    Ghorbani S5 papers · 2026

    Biostatistics, Cancer Research Center, Golestan University of Medical Sciences, Gorgan, Iran.

    Papers in Europe PMC
  6. 06
    Liu Z5 papers · 2026

    Guangdong Provincial Key Laboratory of Translational Cancer Research of Chinese Medicines, Joint International Research Laboratory of Translational Cancer Research of Chinese Medicines, International Institute for Translational Chinese Medicine, School of Pharmaceutical Sciences, Guangzhou University of Chinese Medicine, Guangzhou, China. Electronic address: liuzq@gzucm.edu.cn.

    Papers in Europe PMC
  7. 07
    Wei Z5 papers · 2026

    Department of Burns and Plastic Surgery, The Affiliated Hospital of Zunyi Medical College, Zunyi, China.

    Papers in Europe PMC
  8. 08
    Asadollahi Shahir AA4 papers · 2026

    Department of Addiction Studies, School of Medical, Kashan University of Medical Sciences, Kashan, Iran.

    Papers in Europe PMC
  9. 09
    Chen B4 papers · 2026

    Department of General Surgery, Shanghai Pudong Hospital, Fudan University Pudong Medical Center, Shanghai Key Laboratory of Vascular Lesions Regulation and Remodeling, Shanghai, 201399, China.

    Papers in Europe PMC
  10. 10
    Liu X4 papers · 2026

    Department of TCMs Pharmaceuticals, School of Traditional Chinese Pharmacy, China Pharmaceutical University, Nanjing, 211198, China.

    Papers in Europe PMC

Clinical research

Is a treatment being tested?

11

interventional trials for this specific condition

11 interventional trials matched this specific condition name; 3 currently recruiting in our sample.

Data as of 11 September 2026

11 interventional trials — more than 77.2% of diseases in the trials denominator have none at all (5501 of 7126; this disease is at the 92.8th percentile).

medium confidence · 92.8th percentile (trials denominator)

Recruiting interventional trials

From the matched ClinicalTrials.gov set

11 interventional trials matched after quoted-phrase search and title/condition post-filter.

Observational and natural-history studies

4 observational studies match this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.

Recruiting or not-yet-recruiting

Open the complete matched search on ClinicalTrials.gov

Other registries (secondary)

Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.

raw 11 · after dedupe 11 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 11 · dropped 0 · fetched 2026-07-29

Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri

No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).

Uncertain / not reviewed (11)

Where to find support

Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.

Orphanet entry for Buerger disease — check Associations / patient organisations on that page.

India — NPRD

Last verified 2026-07-26

This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.

Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.

How we counted this

Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.

"Buerger disease" OR "Thromboangiitis obliterans" OR "Buerger's Disease" OR "thromboangiitis obliterans [Buerger's disease]"

Run this search on Europe PMC

ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):

"Buerger disease" OR "Thromboangiitis obliterans" OR "Buerger's Disease" OR "thromboangiitis obliterans [Buerger's disease]"

Interventional trials matched via: phrase (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).

Study-type breakdown: 11 interventional · 4 observational · 1 expanded access. Only interventional studies enter the trial headline.

Query health: ok — strategies attempted: phrase; with hits: phrase

Run this search on ClinicalTrials.gov

Confidence reasoning

  • Preferred label is short or not clearly distinctive
  • No synonyms dropped by stoplist
  • No label/synonym collisions with other diseases in this corpus

Ingested 2026-07-26T23:52:25.210Z